JD Health 2H 2025 Results Projected to Beat Market Expectations -- Market Talk

Dow Jones

01/06

0853 GMT - JD Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. (jason.chau@wsj.com)

(END) Dow Jones Newswires

January 06, 2026 03:53 ET (08:53 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2601860373"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601860373\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601860373?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 16:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601860373","market":"other","top_or_hot":-1,"title":"JD Health 2H 2025 Results Projected to Beat Market Expectations -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0853 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 03:53 ET (08:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health 2H 2025 Results Projected to Beat Market Expectations -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health 2H 2025 Results Projected to Beat Market Expectations -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-06 16:53</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0853 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 06, 2026 03:53 ET (08:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0307460666.USD","symbol_name":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601860373","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601860373","pubTimestamp":1767689580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0853 GMT - JD Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1589":"北水核心资产","BK4614":"Manus概念股","BK4579":"人工智能","BK4588":"碎股","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","06618":"京东健康","BK4551":"寇图资本持仓","BK4509":"腾讯概念","LU0051755006.USD":"摩根大通中国A (dist)","BK1142":"互联网与直销零售","LU1688375341.USD":"贝莱德中国灵活股票基金","IE0008368742.USD":"首域中国增长基金I Acc","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK4220":"综合零售","BK4524":"宅经济概念","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK1615":"港股-互联网","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK4531":"中概回港概念","BK1571":"互联网医疗","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK4526":"热门中概股","BK1515":"抗疫概念","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","BK4503":"景林资产持仓","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4122":"互联网与直销零售","BK1247":"药品零售","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","BK1583":"高瓴概念","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","BK4558":"双十一","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK1591":"就地过年概念","BK4505":"高瓴资本持仓","BK4504":"桥水持仓"},"translate_title":"京东健康2025年下半年业绩预计将超出市场预期——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"06618":1.95},"content_text":"0853 GMT - JD Health's 2H 2025 results should beat estimates, driven by stronger pharmaceutical demand following a spike in influenza cases last quarter, Nomura analysts Rachel Guo and Jialong Shi say in a note. The company's 4Q 2025 revenue is projected to show 22% on-year growth, supported by sales growth in pharmaceuticals, nutrition and medical devices, with effective marketing boosting nutrition brands. Its 4Q operating profit margin is estimated to rise 0.9 percentage point on year, helped by enhanced supply-chain capabilities and rapid growth in high-margin advertising revenue. Nomura raises its 2025-2026 earnings forecasts by 1% on stronger revenue growth expectations. It maintains a buy rating and HK$80 target price on the stock, which last closed at HK$61.35. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 03:53 ET (08:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}